2006 Fiscal Year Final Research Report Summary
The Assessment of gene therapy for bone metastatic lesion of prostate cancer, using Positron Emission Tomography.
| Project/Area Number |
16390464
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hyogo College of Medicine (2005-2006)
Kobe University (2004) |
|---|
Principal Investigator |
GOTOH Akinobu Hyogo College of Medicine, Faculty of Medicine, Professor, 医学部, 教授 (70283885)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SENDA Michio Biomedical Research and Innovation, Image-baseMedicine, Chief Director, 映像医療研究部, 部長 (00216558)
SHIRAKAWA Toshiro Kobe University School of Medicine, International Center for Medical Research and Treatment, Associate Professor, 医学部, 助教授 (70335446)
|
|---|
| Project Period (FY) |
2004 – 2006
|
| Keywords | PET / gene therapy / prostate cancer / [^<18>F]FDG / [^<18>F]FHBG |
|---|
| Research Abstract |
To evaluate the therapeutic effect of the gene therapy for prostate cancer, we performed Positron Emission Tomography (PET) which employed 18F-deoxyglucose ( [18F]FDG) as a tracer, and investigated accumulation of [18F]FDG in tumor. First, we inoculated PC-3 which is a human prostate cancer cell line with Balb/C nude mouse, we formed a subcutaneous or bone tumor of PC-3. After the tumor diameter was 3-5mm (4 weeks later in bone tumor), Ad-OC-TK was injected directly into the subcutaneous tumor or the bone tumor lesion. The doses used were 2.5 x 10^9 and 2.5 x 10^<10> plaque-forming units (PFU) on Day 1 and 8 and we gave VAL daily for 21 d. After 21 d, mice were anesthetized, and injected via tail vein with [18F] FDG (5.3MBq). After lh, we sacrificed mice, and evaluated accumulation of [18F] FDG in tumor. We demonstrated low accumulation of [18F] FDG in tumor treated by gene therapy compared with no treatment. This result suggested that prostate cancer cells treated by gene therapy were low glucose rate of utilization and it was capable of assessing the therapeutic effect of the gene therapy by observing accumulation of [18F] FDG. Furthermore, we similarly tested the transduction effect of HSV-TK gene by injecting 9-[(4-[18F]-fluoro-3-hydroxymethylbuty1)guanine (FHBG) via tail vein.
High accumulation of [18F] FHBG was observed in tumor treated by gene therapy compared with no treatment. This result suggested the possibility of assessing the transduction effect of HSV-TK gene by observing accumulation of [18F] FHBG.
|
